ZYME Looks 47.1% Overvalued on GF Value™

gurufocus.com · 2026-08-26

On August 26, 2026, Zymeworks Inc (NASDAQ: ZYME) shares surged roughly 8% following the FDA's approval of two treatment regimens featuring Jazz Pharmaceuticals'

Read the full story at gurufocus.com →